Thomas E. Stinchcombe

Also affiliated with Cancer Institute (WIA), Parker Institute for Cancer Immunotherapy, Duke Medical Center, Duke Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

1.9Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973

Top 11%

1.9DataRank

Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Papers

Driven by 29 papers — median percentile 89. Top paper: “Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer”.

Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2212083

N/A

7.7DataRank · unranked

1042 citations

Xiaofei Wang, David Kozono, Colleen Watt, Rodney Landrenau, Dennis A. Wigle +16 more

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology(2021)10.1001/jamaoncol.2021.2209

N/A

3.1DataRank · unranked

105 citations

Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.09.013

N/A

2.3DataRank · unranked

79 citations

Mary W. Redman, Susanne M. Arnold, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973

Top 11%

1.9DataRank

Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer

Clinical Lung Cancer(2022)10.1016/j.cllc.2022.04.004

N/A

0.662DataRank · unranked

19 citations

Xiaofei Wang, Christine M. Bestvina, Terence M. Williams, Greg Masters, Anurag Kumar Singh +10 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084

N/A

0.574DataRank · unranked

45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: Results from Cancer and Leukemia Group B 140503 (Alliance)

Journal of Thoracic and Cardiovascular Surgery(2025)10.1016/j.jtcvs.2025.06.007

N/A

0.312DataRank · unranked

7 citations

Bryce Damman, Xiaofei Wang, Moïshe Liberman, Dennis A. Wigle, Ahmad S. Ashrafi +5 more

A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors

UNC Libraries(2020)10.17615/4edx-db25

N/A

0DataRank · unranked

0 citations

Bert H. O’Neil, William Irvin, Kimberly L. Keller, Larry W. Buie, Hanna K. Sanoff +6 more

Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

UNC Libraries(2020)10.17615/05ak-3t14

N/A

0DataRank · unranked

0 citations

You-Han Gao, L. Wei, J. Li, D. Wang, Mark A. Socinski +12 more

Coronary Artery Calcifications and Cardiac Risk After Radiation Therapy for Stage III Lung Cancer

International Journal of Radiation Oncology*Biology*Physics(2021)10.1016/j.ijrobp.2021.08.017

N/A

0DataRank · unranked

35 citations

Hayley Malkin, Nicholas D. Patchett, Kevin A. Pearlstein, Hillary Heiling, Sean McCabe +11 more

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.001

N/A

0DataRank · unranked

32 citations

Mary W. Redman, Lauren A. Byers, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival

Cancer Immunology Immunotherapy(2021)10.1007/s00262-021-02877-9

N/A

0DataRank · unranked

25 citations

Dongfang Tang, Yu Zhao, Hongliang Liu, Sheng Luo, Thomas E. Stinchcombe +7 more

Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patients

Translational research(2021)10.1016/j.trsl.2020.12.009

N/A

0DataRank · unranked

23 citations

Zhensheng Liu, Dongfang Tang, Hongliang Liu, Sheng Luo, Thomas E. Stinchcombe +7 more

Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies

Chinese Clinical Oncology(2022)10.21037/cco-21-110

N/A

0DataRank · unranked

4 citations

Guangyu Yang, Jcm Ho, Tiffany H Leung, Qian Shi, Chen Hu +3 more

Characteristics of toxicity occurrence patterns in concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced non-small cell lung cancer: a pooled analysis based on individual patient data of CALGB/Alliance trials

Translational Cancer Research(2022)10.21037/tcr-22-2006

N/A

0DataRank · unranked

4 citations

HE Qi-hua, Jianrong Zhang, Apar Kishor Ganti, Thomas E. Stinchcombe, Herbert Pang +2 more

Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non–small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance)

Journal of Thoracic and Cardiovascular Surgery(2023)10.1016/j.jtcvs.2023.07.008

N/A

0DataRank · unranked

114 citations

Xiaofei Wang, Bryce Damman, Jennifer Mentlick, Rodney J. Landreneau, Dennis A. Wigle +11 more

Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies

JAMA Network Open(2023)10.1001/jamanetworkopen.2023.19055

N/A

0DataRank · unranked

1 citations

Zachary R. McCaw, Lü Tian, Thomas E. Stinchcombe, Everett E. Vokes, Ethan B. Ludmir +2 more

Convolutional Neural Networks for Segmentation of Malignant Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance)

PubMed(2023)10.48550/arxiv.2312.00223

N/A

0DataRank · unranked

1 citations

Eyjólfur Gudmundsson, Feng Li, Christopher M. Straus, Hedy L. Kindler, Arkadiusz Z. Dudek +5 more

The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer

The Annals of Thoracic Surgery(2024)10.1016/j.athoracsur.2024.01.024

N/A

0DataRank · unranked

35 citations

Cameron N. Fick, James M. Isbell, Jamie E. Chaft, Nasser K. Altorki, Bernard J. Park +13 more

Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance

Cancer(2024)10.1002/cncr.35663

N/A

0DataRank · unranked

3 citations

Briant Fruth, Andreas Rimner, Saiama N. Waqar, M. Mix, W. Jeffrey Petty +5 more

Convolutional Neural Networks for Segmentation of Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance)

Journal of Imaging Informatics in Medicine(2024)10.1007/s10278-024-01092-z

N/A

0DataRank · unranked

3 citations

Eyjólfur Gudmundsson, Feng Li, Christopher M. Straus, Hedy L. Kindler, Arkadiusz Z. Dudek +5 more

Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0762

N/A

0DataRank · unranked

11 citations

Thomas E. Stinchcombe, Mrinal M. Gounder, Gregory M. Coté, Glenn J. Hanna, Bradley Sumrall +16 more

Temporal Trends in the Utilization and Survival Outcomes of Lobar, Segmental, and Wedge Resection for Early-Stage NSCLC, 2004 to 2020

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100794

N/A

0DataRank · unranked

1 citations

Xiaofei Wang, Jianrong Zhang, Thomas E. Stinchcombe, Chi-Fu Jeffrey Yang, Nasser K. Altorki +1 more

Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.06.025

N/A

0DataRank · unranked

53 citations

Xiaofei Wang, Lin Gu, Stephanie Q. Duong, Thomas E. Stinchcombe, Robert A. Kratzke +4 more

Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer

Lung Cancer(2020)10.1016/j.lungcan.2020.01.004

N/A

0DataRank · unranked

16 citations

Apar Kishor Ganti, Thomas E. Stinchcombe, Melisa L. Wong, Jcm Ho, Chen Shen +5 more

Novel Variants of ELP2 and PIAS1 in the Interferon Gamma Signaling Pathway Are Associated with Non–Small Cell Lung Cancer Survival

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-19-1450

N/A

0DataRank · unranked

7 citations

Dongfang Tang, Sen Yang, Hongliang Liu, Sheng Luo, Thomas E. Stinchcombe +6 more

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

UNC Libraries(2020)10.17615/74ry-7003

N/A

0DataRank · unranked

0 citations

Editta Baldini, Pierre-Jean Souquet, Grace K. Dy, Ariel López-Chávez, Federico Cappuzzo +25 more

Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups

UNC Libraries(2020)10.17615/6qqs-re95

N/A

0DataRank · unranked

0 citations

Xiaofei Wang, Daniel J. Sargent, William G. Richards, Everett E. Vokes, Herbert Pang +6 more

Phase I trial of vinflunine and pemetrexed in refractory solid tumors

UNC Libraries(2020)10.17615/ex46-aw91

N/A

0DataRank · unranked

0 citations

Christine M. Walko, Bert H. O’Neil, Wing‐Keung Chiu, Hanna K. Sanoff, Larry W. Buie +5 more

Thomas E. Stinchcombe

Indexed papers

Top data-sharing exemplar

Papers